Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Cuts Q1 Loss on Lower Spending

NEW YORK (GenomeWeb News) – Compugen today reported that its first quarter net loss declined 8 percent as the firm cuts its R&D and SG&A spending.

The Tel Aviv, Israel-based firm reported no revenues for the three-month period ended March 31, compared with revenues of $281,000 for the first quarter of 2008.

Its net loss decreased to $2.3 million, or $.08 per share, from $2.5 million, or $.09 per share, year over year.

The firm's R&D costs declined 30 percent to $1.4 million from $2 million, and its SG&A spending fell from $1 million to $851,000.

Compugen finished the quarter with $4.3 million in cash, cash equivalents, short-term deposits, and, marketable securities. In addition, the firm holds a little more than 2 million shares of stock in Evogene, which it valued at around $4.8 million.

The firm said in a statement that it believes it has sufficient resources to fund its operations through mid-2010.

In early Tuesday trade on the Nasdaq, Compugen's shares were up 12 percent at $1.04.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.